Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Different Doses of SLx-4090 in Combination With a Statin vs. Statin Mono-therapy in Patients With Hyperlipidemia

NCT00810979 is registered in ClinicalTrials.gov with Response Pharmaceuticals as lead sponsor.

NCT NCT00810979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00810979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Different Doses of SLx-4090 in Combination With a Statin vs. Statin Mono-therapy in Patients With Hyperlipidemia
Lead sponsor
Response Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
September 30, 2009
Enrollment
133 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemia